Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04206241
Other study ID # EG0219
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2018
Est. completion date December 31, 2019

Study information

Verified date August 2021
Source Elizabeth Glaser Pediatric AIDS Foundation
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aims to assess the feasibility and, acceptability and effects of implementing HIV testing at birth testing using point-of-care (POC) HIV nucleic acid testing (NAT) in maternity settings.


Description:

This Unitaid-funded study aims to assess the feasibility and, acceptability and effects of implementing HIV testing at birth testing using point-of-care (POC) HIV nucleic acid testing (NAT) in maternity settings. Outcomes measures will include age at uptake of testing, turnaround time from testing to caregiver result receipt, HIV positivity rate, and timing of ART initiation for HIV-positive infants. This study will compare outcomes between HIV-exposed at high vs low risk of maternal HIV transmission. The study will also assess the impact of POC birth testing on retention in care and impact on subsequent testing at 6 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 278833
Est. completion date December 31, 2019
Est. primary completion date November 1, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A to 48 Hours
Eligibility Inclusion Criteria: HIV-exposed infants (HEI) - All HEI who access maternity/post-natal services within 48 hours of life - Tested for HIV at birth using the POC NAT platform - Caregiver provides informed consent for participation Caregivers - Mother/caregiver of an HEI who was offered POC EID at birth - Able to provide informed consent to participate in the study Health workers - All health workers working in maternity services in the study sites - Provides informed consent to be interviewed Key informants (laboratory managers and program leads/focal persons) - Health managers working in the field of pediatric HIV services or PMTCT - Provides informed consent to be interviewed Exclusion Criteria: HIV-exposed infants (HEI) - HEI tested for HIV using conventional EID at project sites - HEI whose caregivers refuse birth testing - HEI where the clinician deems there is a contra-indication for sample collection for birth testing (e.g. severe hemophilia) Caregivers - Caregivers of HEI who cannot legally provide consent to participate in the study Health workers - Healthcare workers who do not make use of EID or results of EID Key informants - Key informants who cannot legally provide consent to participate in the study

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Point of care early infant diagnosis (POC EID)
HIV testing where the blood sample is processed at either the facility itself or a nearby site that is closer to the facility than a laboratory. With POC EID, blood samples do not have to travel to the laboratory for processing.

Locations

Country Name City State
Zimbabwe Beitbridge District Hospital Beitbridge
Zimbabwe Bindura Provincial Hospital Bindura
Zimbabwe Chegutu District Hospital Chegutu
Zimbabwe Norton Hospital Chegutu
Zimbabwe Chiredzi District Hospital Chiredzi
Zimbabwe Gweru Provincial Hospital Gweru
Zimbabwe Victoria Falls District Hospital Hwange
Zimbabwe Kadoma District Hospital Kadoma
Zimbabwe Kwekwe General Hospital Kwekwe
Zimbabwe Masvingo Provincial Hospital Masvingo

Sponsors (2)

Lead Sponsor Collaborator
Elizabeth Glaser Pediatric AIDS Foundation UNITAID

Country where clinical trial is conducted

Zimbabwe, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of eligible HEI who present to pilot facilities who receive POC EID testing at birth Number of eligible HEI who received POC EID divided by the total number of eligible HEI 18 months
Secondary Proportion of tested HEI whose caregivers receive results of the POC EID birth testing Number of HEI whose caregivers received results of the POC EID birth testing, divided by the number of HEI who received POC EID birth testing 18 months
Secondary Average number of days between sample collection of HEI and results received by caregiver Date HEI sample collected minus date results received 18 months
Secondary Proportion of HEI tested at birth who are HIV positive Number of HEI tested at birth who are HIV positive divided by the number of HEI tested at birth 18 months
Secondary Proportion of HIV-infected infants tested at birth who are started on ART within 2 weeks of the birth test Number of HIV-infected infants tested at birth who are started on ART within 2 weeks of the birth test, divided by the number of HIV-infected infants tested at birth 18 months
Secondary Average number of days between sample collection of HEI and initiation on ART for infants testing HIV-positive Date of sample collection of HEI minus date of date of ART initiation on ART for infants testing HIV-positive 18 months
Secondary Proportion of infants testing HIV negative at birth and who return for testing at 6-8 weeks Number of infants testing HIV-negative at birth who return for testing at 6-8 weeks, divided by the number of infants who tested HIV-negative at birth 18 months
Secondary Proportion of infants who test HIV-positive at 6-8 weeks of those who test negative at birth Number of infants who test HIV-positive at 6-8 weeks divided by those who tested HIV-negative at birth 18 months
Secondary The retention in care of positively-identified infants on birth testing for the first 3 and/or 6 months of life Number of infants who tested HIV-positive at birth in care at 3 and/or 6 months of life, divided by the number who tested HIV-positive at birth 18 months
Secondary Proportion of HEI tested at birth who meet criteria for high risk of vertical transmission Number of HEI tested at birth who meet the criteria for high risk of vertical transmission divided by the number who meet the criteria for high risk of vertical transmission 18 months
Secondary Proportion of high-risk infants according to the risk screening tool who test HIV-positive at birth Number of high-risk infants according to the risk screening tool who test HIV-positive at birth, divided by the number of high-risk infants according to the risk screening tool 18 months
Secondary Proportion of low-risk infants according to the risk screening tool who test HIV-positive at birth Number of low-risk infants according to the risk screening tool who test HIV-positive at birth, divided by the number of low-risk infants according the risk screening tool 18 months
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2